Heading into 2024, expectations for biotech venture capital (VC) and private equity (PE) investments were low following two lackluster years, but as we wrap up Q1, those expectations have been turned on their head after a strong start to the year. This leads us to question whether these early tailwinds are here to stay?

Already, several themes have emerged as value drivers in 2024, including artificial intelligence (AI), weight loss, and cell and gene therapy manufacturing. Companies that are still standing in these sectors would be well advised to make strong moves toward their next growth milestone. READ MORE